Rein Therapeutics develops inhaled drug candidates for rare lung diseases, led by a treatment for idiopathic pulmonary fibrosis. It last closed at $0.36 on Nov 17, down 10.90% on the day. In the past 30 days there were 1 dark pool print totaling $188K, the largest $188K.
RNTX · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 70% below its 20 day and 94% below its 50 day average. It is 178% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the Pivot S1 at $0.32, and the nearest resistance the Pivot at $0.36.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 22.1%/day
Key levels
$2.1052 week high+483.3%
$0.99200 day average+175.0%
$0.77100 day average+113.9%
$0.6950 day average+91.7%
$0.65Swing high (Oct 21)+80.6%
$0.6020 day average+66.7%
$0.40Pivot R1+11.1%
$0.36Pivot+0.0%
$0.36Last close
$0.32Pivot S1−11.1%
$0.2852 week low−22.2%
Indicators
RSI (14)
23.81
Oversold below 30
Oversold
MACD
-0.06
Below its signal line
Bearish
Stochastic
18.5
Near the bottom of its range
Oversold
ADX (14)
22.3
Weak trend
Williams %R
-84.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-274.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−46.6%
Change over 10 sessions
Bearish
ATR (14)
$0.08
Typical daily range, 22.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchOversold
VolatilityHigh, 50.3%/day
Key levels
$2.1052 week high+483.3%
$0.99200 day average+175.0%
$0.77100 day average+113.9%
$0.6950 day average+91.7%
$0.65Swing high (Oct 21)+80.6%
$0.6020 day average+66.7%
$0.40Pivot R1+11.1%
$0.36Pivot+0.0%
$0.36Last close
$0.32Pivot S1−11.1%
$0.2852 week low−22.2%
Indicators
RSI (14)
29.97
Oversold below 30
Oversold
MACD
-0.15
Below its signal line
Bearish
Stochastic
12.1
Near the bottom of its range
Oversold
ADX (14)
11.7
No clear trend
Williams %R
-89.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-242.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−54.6%
Change over 10 sessions
Bearish
ATR (14)
$0.18
Typical daily range, 50.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for RNTX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how RNTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90D
No whale options trades in RNTX in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RNTX is in one of them and how their past RNTX trades turned out.
Rein Therapeutics is a biopharmaceutical company based in Austin, Texas, that develops treatments for rare lung diseases with few effective options. Its lead candidate, LTI-03, is an inhaled peptide being studied for idiopathic pulmonary fibrosis, a progressive lung disease. The company has paused work on its other candidates while it focuses on LTI-03. Its target patients are people living with lung fibrosis and related conditions.